13 Best Psychedelic Stocks to Invest in Now

Page 7 of 11

5. Atai Life Sciences N.V. (NASDAQ:ATAI)

Number of Hedge Fund Holders: 17 

Atai Life Sciences N.V. (NASDAQ:ATAI), a clinical-stage biopharmaceutical company, is developing innovative psychedelic-based treatments for mental health disorders, including treatment-resistant depression (TRD). The company focuses on therapies with short in-clinic treatment durations that provide rapid and durable antidepressant effects.

Recent developments highlight a strategic merger with Beckley Psytech, aimed at consolidating expertise and late-stage assets to accelerate the delivery of impactful mental health therapies. This move is expected to strengthen the corporation’s position as a global leader in psychedelic therapeutics, making Atai Life Sciences N.V. (NASDAQ:ATAI) one of the best psychedelic stocks for investors focused on innovative treatments.

In clinical progress, BPL-003 (intranasal mebufotenin benzoate) showed positive topline results from the blinded stage of its Phase 2b trial in TRD patients. The therapy met primary and secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects lasting up to eight weeks after a single dose. Results from the open-label extension are anticipated in Q3 2025. Atai Life Sciences N.V. (NASDAQ:ATAI) plans to file an End-of-Phase 2 meeting request with the FDA in Q3 2025 to advance BPL-003’s clinical development pathway.

Financially, Atai Life Sciences N.V. (NASDAQ:ATAI) has raised nearly $140 million in 2025, reflecting strong investor confidence in its strategy and pipeline. Positive clinical data and strategic initiatives drove significant stock momentum in August 2025, underscoring market optimism.

Page 7 of 11